Dynamic profile for the detection of anti-SARS-CoV-2 antibodies using four immunochromatographic assays

Baptiste Demey^a,b, Nagib Daher^c , Catherine François^a,b, Jean-Philippe Lanoix^b,d, Gilles Duverlie^a,b, Sandrine Castelain^a,b, Etienne Brochot^a,b, ∗

1. Department of Virology, Amiens University Medical Center, Amiens, France
2. AGIR Research Unit, EA4294, Jules Verne University of Picardie, Amiens, France
3. Department of Gynecology-Obstetrics, University Hospital, Amiens
4. Infectious Diseases Department, University Hospital, Amiens

Analytical performance of lateral flow immunoassay for SARS-CoV-2 exposure screening on venous and capillary blood samples

Margaret A. Black, MD¹*, Guomiao Shen, PhD^1*, Xiaojun Feng, PhD^1*, Wilfredo F. Garcia, Beltran, MD, PhD^3,4, Yang Feng, PhD², Varshini Vasudevaraja, MS¹, Douglas Allison, MD¹, Lawrence H. Lin, MD, PhD¹, Tatyana Gindin MD, PhD¹, Michael Astudillo, MD³, Diane Yang, PhD³, Mandakolathur Murali, MD^3,5, A. John Iafrate, MD, PhD³, George Jour, MD^1**, Paolo, Cotzia, MD^1**, Matija Snuderl, MD^1**

1. Department of Pathology, NYU Langone Health, New York City, NY
2. Department of Biostatistics, NYU School of Global Public Health, New York City, NY
3. Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
4. Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA
5. Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA

* These authors contributed equally to this work.
** Corresponding authors

Singapore’s Response to Covid-19

Abstract This chapter will discuss Singapore’s response to the Covid-19 pandemic, focusing in particular on how it has mobilised and adapted its policy capacities to deal with the pandemic. I will also discuss the new capacities that were established this period. In focusing on how policy capacities were drawn upon or created in its Covid-19 response, this chapter will provide readers with an understanding of the various policy capacities that are necessary for responding to pandemics and other healthcare crises, as well as the capacity limitations or deficiencies that may have posed challenges for policymakers.

Keywords Covid-19 · Singapore · Pandemic response · Policy capacity

Evaluation of Six Commercial Mid- to High-Volume Antibody and Six Point-of-Care Lateral Flow Assays for Detection of SARS-CoV-2 Antibodies

iDCarmen L. Charlton,^a,b,c Jamil N. Kanji,^a,d Kam Johal,a Ashley Bailey,^a Sabrina S. Plitt,^e Clayton MacDonald,^a,b Andrea Kunst,^fEmily Buss,^f Laura E. Burnes,^a,b Kevin Fonseca,^a,g Byron M. Berenger,^a,h Kareena Schnabl,^b,f Jia Hu,^i,j William Stokes, ^k Nathan Zelyas,^a,b Graham Tipplesa,^c,l

Evaluating ten commercially-available SARS-CoV-2 rapid 3 serological tests using the STARD (Standards for 4 Reporting of Diagnostic Accuracy Studies) method.

Laurent DORTET,^1,2,$ Jean-Baptiste RONAT,^2,3,$ Christelle VAULOUP-FELLOUS,^4,5$Céline LANGENDORF,⁶ David-Alexis MENDELS,⁷ Cécile EMERAUD, ^1,2 Saoussen OUESLATI,² Delphine GIRLICH,² Anthony CHAUVIN,⁸ Ali AFDJEI⁹ , Sandrine BERNABEU,^1,2 Samuel LE PAPE,⁴ Rim KALLALA, ⁴ Alice ROCHARD, ² Celine VERSTUYFT,¹⁰ Nicolas FORTINEAU,^1,2 Anne-Marie ROQUE-AFONSO,^4,5 and Thierry NAAS^1,2*